| Name | Title | Contact Details |
|---|---|---|
Marc Levine |
Director of Ethics, Risk and Compliance | Profile |
Monica Watson |
Vice President, Legal Head, Integrated Marketing and Customer Experience | Profile |
Melissa Lozner |
Vice President, Head of Ethics, Risk and Compliance | Profile |
Jeffrey Donohue |
Executive Director and Associate General Counsel, Global Head NIBR Legal Transactions | Profile |
Mark Rimbergas |
Associate Director, Global Compliance | Profile |
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
B.F. Ascher is a privately held over-the-counter healthcare company
isotechnika is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.
Qualyst is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.